The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma.
Immunohistochemistry
Meningioma
Prognosis
Recurrence-free survival
SSTR
Somatostatin receptor
Tissue microarray
Journal
Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
07
06
2021
accepted:
19
09
2021
revised:
08
09
2021
pubmed:
4
10
2021
medline:
6
8
2022
entrez:
3
10
2021
Statut:
ppublish
Résumé
The expression of somatostatin receptors in meningioma is well established. First, suggestions of a prognostic impact of SSTRs in meningioma have been made. However, the knowledge is based on few investigations in small cohorts. We recently analyzed the expression of all five known SSTRs in a large cohort of over 700 meningiomas and demonstrated significant correlations with WHO tumor grade and other clinical characteristics. We therefore expanded our dataset and additionally collected information about radiographic tumor recurrence and progression as well as clinically relevant factors (gender, age, extent of resection, WHO grade, tumor location, adjuvant radiotherapy, neurofibromatosis type 2, primary/recurrent tumor) for a comprehensive prognostic multivariate analysis (n = 666). The immunohistochemical expression scores of SSTR1, 2A, 3, 4, and 5 were scored using an intensity distribution score ranging from 0 to 12. For recurrence-free progression analysis, a cutoff at an intensity distribution score of 6 was used. Univariate analysis demonstrated a higher rate of tumor recurrence for increased expression scores for SSTR2A, SSTR3, and SSTR4 (p = 0.0312, p = 0.0351, and p = 0.0390, respectively), while high expression levels of SSTR1 showed less frequent tumor recurrences (p = 0.0012). In the Kaplan-Meier analysis, a higher intensity distribution score showed a favorable prognosis for SSTR1 (p = 0.0158) and an unfavorable prognosis for SSTR2A (0.0143). The negative prognostic impact of higher SSTR2A expression remained a significant factor in the multivariate analysis (RR 1.69, p = 0.0060). We conclude that the expression of SSTR2A has an independent prognostic value regarding meningioma recurrence.
Identifiants
pubmed: 34601710
doi: 10.1007/s10143-021-01651-w
pii: 10.1007/s10143-021-01651-w
pmc: PMC9349155
doi:
Substances chimiques
Receptors, Somatostatin
0
somatostatin receptor 2
D73QL0OMU2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2671-2679Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21:v1–v100. https://doi.org/10.1093/neuonc/noz150
doi: 10.1093/neuonc/noz150
pubmed: 31675094
pmcid: 6823730
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383-391. https://doi.org/10.1016/S1470-2045(16)30321-7
doi: 10.1016/S1470-2045(16)30321-7
pubmed: 27599143
Lemee JM, Corniola MV, Meling TR (2020) Benefits of re-do surgery for recurrent intracranial meningiomas. Sci Rep 10:303. https://doi.org/10.1038/s41598-019-57254-5
doi: 10.1038/s41598-019-57254-5
pubmed: 31941981
pmcid: 6962359
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
pubmed: 27157931
Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hanggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694. https://doi.org/10.1016/S1470-2045(17)30155-9
doi: 10.1016/S1470-2045(17)30155-9
pubmed: 28314689
Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H, Perry A, Sahm F, Sloan A, Von Deimling A, Wen PY, Aldape K, Zadeh G, International Consortium on M (2019) Molecular and translational advances in meningiomas. Neuro Oncol 21:i4–i17. https://doi.org/10.1093/neuonc/noy178
doi: 10.1093/neuonc/noy178
pubmed: 30649490
pmcid: 6347079
Dash A, Chakraborty S, Pillai MR, Knapp FF Jr (2015) Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm 30:47–71. https://doi.org/10.1089/cbr.2014.1741
doi: 10.1089/cbr.2014.1741
pubmed: 25710506
Reubi JC (2004) Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1):51–56. https://doi.org/10.1159/000080742
doi: 10.1159/000080742
pubmed: 15477718
Minutoli F, Amato E, Sindoni A, Cardile D, Conti A, Herberg A, Baldari S (2014) Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature. Cancer Biother Radiopharm 29:193–199. https://doi.org/10.1089/cbr.2013.1599
doi: 10.1089/cbr.2013.1599
pubmed: 24811687
Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, Ilhan H, Pangalu A, Weller M, Tonn JC, Sommerauer M, Albert NL (2016) Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol 18:1538–1547. https://doi.org/10.1093/neuonc/now060
doi: 10.1093/neuonc/now060
pubmed: 27106404
pmcid: 5063513
Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66:155–166. https://doi.org/10.1023/b:neon.0000013498.19981.55
doi: 10.1023/b:neon.0000013498.19981.55
pubmed: 15015781
Barresi V, Alafaci C, Salpietro F, Tuccari G (2008) Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep 20:485–492
pubmed: 18695896
Silva CB, Ongaratti BR, Trott G, Haag T, Ferreira NP, Leaes CG, Pereira-Lima JF, Oliveira Mda C (2015) Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol 8:13185–13192
pubmed: 26722517
pmcid: 4680462
Behling F, Fodi C, Skardelly M, Renovanz M, Castaneda S, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J (2021) Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential. Neurosurg Rev. https://doi.org/10.1007/s10143-021-01552-y
doi: 10.1007/s10143-021-01552-y
pubmed: 34601710
pmcid: 8827336
Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, Wang Q, Sulman EP, Adeberg S, Koch A, Okuducu AF, Brehmer S, Schittenhelm J, Becker A, Brokinkel B, Schmidt M, Ull T, Gousias K, Kessler AF, Lamszus K, Debus J, Mawrin C, Kim YJ, Simon M, Ketter R, Paulus W, Aldape KD, Herold-Mende C, von Deimling A (2016) TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst 108. https://doi.org/10.1093/jnci/djv377
Perez-Magan E, Rodriguez de Lope A, Ribalta T, Ruano Y, Campos-Martin Y, Perez-Bautista G, Garcia JF, Garcia-Claver A, Fiano C, Hernandez-Moneo JL, Mollejo M, Melendez B (2010) Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol 12:1278–1290. https://doi.org/10.1093/neuonc/noq081
doi: 10.1093/neuonc/noq081
pubmed: 20685720
pmcid: 3018937
Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C (2004) Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 1014:121–131. https://doi.org/10.1196/annals.1294.012
doi: 10.1196/annals.1294.012
pubmed: 15153426
Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB (1994) All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 198:605–612. https://doi.org/10.1006/bbrc.1994.1088
doi: 10.1006/bbrc.1994.1088
pubmed: 7905265
Reubi JC, Laissue JA (1995) Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 16:110–115. https://doi.org/10.1016/s0165-6147(00)88992-0
doi: 10.1016/s0165-6147(00)88992-0
pubmed: 7792931
Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733–1742. https://doi.org/10.1093/annonc/mdl105
doi: 10.1093/annonc/mdl105
pubmed: 16801334
Szende B, Juhasz E, Lapis K, Schally AV (1992) Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160. Urol Res 20:383–386. https://doi.org/10.1007/BF00294492
doi: 10.1007/BF00294492
pubmed: 1361084
Koper JW, Markstein R, Kohler C, Kwekkeboom DJ, Avezaat CJ, Lamberts SW, Reubi JC (1992) Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 74:543–547. https://doi.org/10.1210/jcem.74.3.1346787
doi: 10.1210/jcem.74.3.1346787
pubmed: 1346787